Drug · DIN 02409607
TAFINLAR
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 27, 2016; first marketed August 28, 2013.
- Drug Identification Number (DIN)
- 02409607
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Dabrafenib L01EC02
- Class
- Human
- Record last updated
- March 20, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DABRAFENIB (DABRAFENIB MESYLATE) | 50 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 31, 2015: NOC 17151New Drug Submission (NDS) · Transfer of Drug Identification Number(s)
- July 16, 2013: NOC 14554New Drug Submission (NDS)
Other DINs named TAFINLAR
- DIN 02409615 · Marketed
- DIN 02540053 · Marketed